Arterioportal shunt(APS) is an organic communication between the hepatic arterial system and the portal venous system. The APS is one of the major causes of transient hepatic attenuation differences on dynamic compute...Arterioportal shunt(APS) is an organic communication between the hepatic arterial system and the portal venous system. The APS is one of the major causes of transient hepatic attenuation differences on dynamic computed tomography(CT) or magnetic resonance imaging(MRI). This condition is usually associated with trauma,liver cirrhosis,and malignancies of the liver. However,there has been no report about oxaliplatininduced APS. A 41-year-old male was diagnosed with Stage ⅢB gastric cancer. The patient initially underwent neoadjuvant chemotherapy with capecitabine and oxaliplatin After 3 cycles of therapy,the mass had markedly decreased,and a total gastrectomy with splenectomy was performed. Since the malignancy was locally invasive,the patient was continued on the same regimen of the adjuvant chemotherapy. After 3 more cycles,a computed tomography revealed a 1 cm sized arterial-enhancing nodule in the right lobe of the liver. An MRI revealed an arterial enhancing lesion,and a positron emission tomography CT scan showed a hypermetabolic lesion in the same portion of the liver. We tried to perform a liver biopsy; however,an ultrasonography could not detect any mass. A presumptive diagnosis of an APS due to a recurred cancer was made. We found a similar but slightly different case report of an oxaliplatin-induced liver injury,mimicking a metastatic tumor on an MRI. Based on a prior report,the patient was continuedon treatment with adjuvant chemotherapy following discontinuation of oxaliplatin. After 2 cycles,the arterial enhancing liver mass resolved,supporting the final diagnosis of an APS,related to oxaliplatin-induced sinusoidal injury. The patient has not experienced any a relapse after two years of additional follow up recurrent gastric cancer upon interpretation of multiple imaging modalities.展开更多
基金The National Research Foundation of Korea(NRF)funded by the Ministry of Science,ICT,and Future Planning,No.NRF-2015R1A5A2009070research fund from Chosun University,2015
文摘Arterioportal shunt(APS) is an organic communication between the hepatic arterial system and the portal venous system. The APS is one of the major causes of transient hepatic attenuation differences on dynamic computed tomography(CT) or magnetic resonance imaging(MRI). This condition is usually associated with trauma,liver cirrhosis,and malignancies of the liver. However,there has been no report about oxaliplatininduced APS. A 41-year-old male was diagnosed with Stage ⅢB gastric cancer. The patient initially underwent neoadjuvant chemotherapy with capecitabine and oxaliplatin After 3 cycles of therapy,the mass had markedly decreased,and a total gastrectomy with splenectomy was performed. Since the malignancy was locally invasive,the patient was continued on the same regimen of the adjuvant chemotherapy. After 3 more cycles,a computed tomography revealed a 1 cm sized arterial-enhancing nodule in the right lobe of the liver. An MRI revealed an arterial enhancing lesion,and a positron emission tomography CT scan showed a hypermetabolic lesion in the same portion of the liver. We tried to perform a liver biopsy; however,an ultrasonography could not detect any mass. A presumptive diagnosis of an APS due to a recurred cancer was made. We found a similar but slightly different case report of an oxaliplatin-induced liver injury,mimicking a metastatic tumor on an MRI. Based on a prior report,the patient was continuedon treatment with adjuvant chemotherapy following discontinuation of oxaliplatin. After 2 cycles,the arterial enhancing liver mass resolved,supporting the final diagnosis of an APS,related to oxaliplatin-induced sinusoidal injury. The patient has not experienced any a relapse after two years of additional follow up recurrent gastric cancer upon interpretation of multiple imaging modalities.
